96.20
+3.17
(3.41%)
May 23 - Close
NASDAQ
real-time data -
Disclaimer
Currency in USD
| Range | 89.33 - 96.95 |
| 52 week | 41.26 - 101.57 |
| Open | 92.01 |
| Vol / Avg. | 822,706.00/1.12M |
| Mkt cap | 7.00B |
| P/E | - |
| Div/yield | - |
| EPS | -2.51 |
| Shares | 72.74M |
| Beta | 1.15 |
| Inst. own | 105% |
Events
Aug 2, 2013
Q2 2013 Onyx Pharmaceuticals Earnings Release
May 21, 2013
Onyx Pharmaceuticals at UBS Global Healthcare Conference
May 14, 2013
Onyx Pharmaceuticals at Bank of America Merrill Lynch Health Care Conference
May 7, 2013
Q1 2013 Onyx Pharmaceuticals Earnings Conference Call
May 3, 2013
Q1 2013 Onyx Pharmaceuticals Earnings Release
Mar 14, 2013
Onyx Pharmaceuticals Analyst Day
Mar 5, 2013
Onyx Pharmaceuticals at Cowen Health Care Conference
Feb 26, 2013
Onyx Pharmaceuticals at Citi Global Healthcare Conference
|
More events from DailyFinance »
|
Key stats and ratios
| Q1 (Mar '13) | 2012 | |
| Net profit margin | -23.14% | -51.85% |
| Operating margin | -19.57% | -74.88% |
| EBITD margin | - | -50.28% |
| Return on average assets | -8.92% | -13.59% |
| Return on average equity | -13.65% | -22.85% |
| Employees | 741 | - |
| Carbon Disclosure Rating | - | - |
Address
249 E. Grand Avenue
SOUTH SAN FRANCISCO, CA 94080
United States - Map
+1-650-2660000 (Phone)
+1-650-2660100 (Fax)
SOUTH SAN FRANCISCO, CA 94080
United States - Map
+1-650-2660000 (Phone)
+1-650-2660100 (Fax)
Website links
External links
Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Research Reports - Reuters
Discussion Group - Google Finance
Volume delayed by 15 mins.
Advertisement
Description
Onyx Pharmaceuticals, Inc. (Onyx) is a biopharmaceutical company. The Company is developing therapies that target the molecular mechanisms that cause cancer. The Company has built two franchise platforms: one in kinase inhibition and one in proteasome inhibition. In its kinase inhibitor franchise, its product, Nexavar (sorafenib) tablets is approved for unresectable liver cancer and advanced kidney cancer. unresectable liver cancer and advanced kidney cancer. With its development and marketing partner Bayer HealthCare Pharmaceuticals Inc., or Bayer, the Company shares equally in the profits and losses of Nexavar worldwide except Japan. A kinase inhibitor, regorafenib, is an investigational agent that has already demonstrated positive Phase 3 survival data in metastatic colorectal cancer, and is being evaluated in a Phase 3 study in gastrointestinal stromal tumors (GIST).
Officers and directors
| N. Anthony Coles Jr., M.D. | Chairman of the Board, President, Chief Executive Officer | |
| Matthew K. Fust | Chief Financial Officer, Executive Vice President | |
| Suzanne M. Shema J.D. | Executive Vice President, General Counsel, Corporate Secretary | |
| Pablo J. Cagnoni M.D. | Executive Vice President - Global Research & Development and Technical Operations | |
| Juergen Lasowski Ph.D. | Executive Vice President - Corporate Development and Strategy | |
| Helen I. Torley | Executive Vice President, Chief Commercial Officer | |
| Kaye I. Foster-Cheek | Senior Vice President - Global Human Resources | |
| Julianna R. Wood | Vice President - Public Affairs | |
| Paul Goddard Ph.D. | Lead Independent Director | |
| Antonio J. Grillo-Lopez M.D. | Independent Director |